A systematic literature review and meta-analysis of the effect of psilocybin and methylenedioxymethamphetamine on mental, behavioural or developmental disorders
Australian & New Zealand Journal of Psychiatry March 12, 2022 Steve Kisely, Mark Connor, Andrew A. Somogyi et al. 36 citations
A systematic review of randomized controlled trials found that MDMA and psilocybin, given with psychological support, may reduce symptoms in highly selected populations under close supervision. The strongest evidence was for MDMA in post-traumatic stress disorder, with a large effect compared to active controls (standardized mean difference = -0.86). Psilocybin showed small benefits for social anxiety in adults with autism and was as effective as escitalopram for long-standing depression on the primary outcome, though most secondary benefits were not significant after correction. Both drugs were well tolerated, but overall certainty of evidence was low or very low.